Member, Digestive Diseases/Gastroenterology, UCLA School of Medicine

Gastroenterology

Dr. Kevin J. Horgan, MD

Kevin Horgan is an expert in the field of Gastroenterology. Kevin Horgan is also a published doctor. He has 49 paper published. The most recent paper is: Ductal carcinoma in situ of the breast: the clinical significance of histological classification.

Publications

Evaluation of Oral Beclomethasone Dipropionate for Prevention of Acute Graft-versus-host Disease.
Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in...
Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemo...
Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.
Ductal carcinoma in situ of the breast: the clinical significance of histological classification.
Stressful life events and difficulties and onset of breast cancer: case-control study.
Dual immunocytochemical analysis of oestrogen and epidermal growth factor receptors in human breast cancer.
Mitogenicity of human fibroblasts in vivo for human breast cancer cells.
Safe margins in the excision of primary cutaneous melanoma.
Practical advice on clinical decision making during neoadjuvant chemotherapy for primary breast cancer.
Postoperative wound complications and systemic recurrence in breast cancer.
Follow-up of patients with a thin melanoma.
Management of malignant melanoma of the head and neck.
Expression of COX-2, NF-kappaB-p65, NF-kappaB-p50 and IKKalpha in malignant and adjacent normal human colorectal tissue.
CD45RB expression defines two interconvertible subsets of human CD4+ T cells with memory function.
Selective expression of integrin alpha 4 beta 7 on a subset of human CD4+ memory T cells with Hallmarks of gut-trophism.
Crosslinking of the T cell-specific accessory molecules CD7 and CD28 modulates T cell adhesion.
Differential expression of VLA-alpha 4 and VLA-beta 1 discriminates multiple subsets of CD4+CD45R0+ "memory" T cells.
Postthymic differentiation of CD4 T lymphocytes: naive versus memory subsets and further specialization among memory cells.
Roles of adhesion molecules in T-cell recognition: fundamental similarities between four integrins on resting human T cells (LFA-1, VLA-4, VLA-5, VLA-6) in expression,...
Remote T cell co-stimulation via LFA-1/ICAM-1 and CD2/LFA-3: demonstration with immobilized ligand/mAb and implication in monocyte-mediated co-stimulation.
Costimulation of proliferative responses of resting CD4+ T cells by the interaction of VLA-4 and VLA-5 with fibronectin or VLA-6 with laminin.
Hyporesponsiveness of "naive" (CD45RA+) human T cells to multiple receptor-mediated stimuli but augmentation of responses by co-stimuli.
The LFA-1 ligand ICAM-1 provides an important costimulatory signal for T cell receptor-mediated activation of resting T cells.
A randomized controlled trial of prophylactic isolated cytotoxic perfusion for poor-prognosis primary melanoma of the lower limb.
Analysis of T cell stimulation by superantigen plus major histocompatibility complex class II molecules or by CD3 monoclonal antibody: costimulation by purified adhesi...
Antiproliferative effects of idoxifene in a placebo-controlled trial in primary human breast cancer.
Regulated expression and binding of three VLA (beta 1) integrin receptors on T cells.
Four molecular pathways of T cell adhesion to endothelial cells: roles of LFA-1, VCAM-1, and ELAM-1 and changes in pathway hierarchy under different activation conditi...
Activation-independent binding of human memory T cells to adhesion molecule ELAM-1.
CD31 expressed on distinctive T cell subsets is a preferential amplifier of beta 1 integrin-mediated adhesion.
Functional relevance of antiemetic control. Experience using the FLIE questionnaire in a randomised study of the NK-1 antagonist aprepitant.
The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemothe...
Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemot...
Assessing the impact of chemotherapy-induced nausea and vomiting on patients'' daily lives: a modified version of the Functional Living Index-Emesis (FLIE) with 5-day ...
Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT 3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and...
Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists.
Immunomagnetic purification of T cell subpopulations.
Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab.
Peptic ulcer and bleeding events associated with rofecoxib in a 3-year colorectal adenoma chemoprevention trial.
A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas.
Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.
Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a...
The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controll...
Aprepitant: an oral NK1 antagonist for the prevention of nausea and vomiting induced by highly emetogenic chemotherapy.
The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, pla...
A randomized, double-blind comparison of the NK1 antagonist, aprepitant, versus ondansetron for the prevention of postoperative nausea and vomiting.
Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy.

Doctors Specialties

Gastroenterology

Accepted Insurances

Education

UCLA Medical Center
Johns Hopkins University
University College Cork Faculty of Medicine

Hospital

Ronald Reagan UCLA Medical Center

Helpful Reviews

Give Anonymous Review

Similar Doctors

	Dr. Payman Khorrami, MD This Doctor is OpenDoctor Recommended.
	Dr. Parviz Gholami, MD This Doctor is OpenDoctor Recommended.
	Dr. Dennis M. Jensen, MD This Doctor is OpenDoctor Recommended.
	Dr. Said Rahban, MD This Doctor is OpenDoctor Recommended.
	Dr. Oliver A. Goldsmith, MD This Doctor is OpenDoctor Recommended.
	Dr. Dung Nguyen, MD This Doctor is OpenDoctor Recommended.
	Dr. James Sul, MD This Doctor is OpenDoctor Recommended.
	Dr. Harpreet K. Sekhon, MD This Doctor is OpenDoctor Recommended.
	Dr. David Q. Shih, MD
	Dr. Phillip S. Ge, MD
	Dr. Donald C. Gerety, MD This Doctor is OpenDoctor Recommended.
	Dr. Stanley C. Karz, MD This Doctor is OpenDoctor Recommended.
	Dr. Paul J. Korc, MD This Doctor is OpenDoctor Recommended.